Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
This unique record was made possible by collating hard copies of the books in a structured manner
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Fujifilm India recently introduced a “Covid-19 Pneumonia Image Analysis Program” that helps in diagnosing chest CT images that helps in findings of Covid-19 pneumonia
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Subscribe To Our Newsletter & Stay Updated
